Status:
WITHDRAWN
Resveratrol and Human Hepatocyte Function in Cancer
Lead Sponsor:
University of Louisville
Conditions:
Liver Cancer
Eligibility:
All Genders
21-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine if Resveratrol, a nutritional supplement, shows a beneficial effect in the cellular function of normal liver cells and diseased liver cells (cancer cells) in ...
Detailed Description
Hepatic function will be assessed by standard laboratory techniques. Hepatocyte signaling pathway proteins will be measured using western blot analysis for protein expression and polymerase chain reac...
Eligibility Criteria
Inclusion
- Undergoing elective liver resection for liver cancer
Exclusion
- Inability to speak or read English
- Sclerosing cholangitis, hemochromatosis, hepatic encephalopathy, acute hepatic failure
- History of daily alcohol intake
- Presence of human immunodeficiency virus
- Presence of significant renal dysfunction as defined by baseline serum creatinine \> 2.0 mg/dl or need/impending need for chronic dialysis therapy
- Known allergy to the study medication
- Pregnancy, lactating women, women contemplating pregnancy during the study period
Key Trial Info
Start Date :
December 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT02261844
Start Date
December 1 2015
End Date
June 1 2016
Last Update
March 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Louisville
Louisville, Kentucky, United States, 40202